Navigation Links
Kinase Inhibitors: Global Markets -- Focus on the U.S.
Date:9/6/2012

NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Kinase Inhibitors: Global Markets -- Focus on the U.S.

http://www.reportlinker.com/p0958097/Kinase-Inhibitors-Global-Markets----Focus-on-the-US.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

 

INTRODUCTION

 

STUDY OBJECTIVES

 

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for kinase inhibitors. The key objective is to present a comprehensive analysis and the future direction of kinase inhibitors to provide an important tool for the usage of these types of enzyme inhibitors.

 

This report explores present and future strategies within the kinase inhibitors market, which includes tyrosine inhibitors, multi-target kinase inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase inhibitors. The direction of the market, its setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of enzyme inhibitors are also examined in the report.

 

A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2011 through 2016.

 

Applications for kinase inhibitors are also discussed separately in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and a summary of patents awarded in each category.

 

REASONS FOR DOING THIS STUDY

 

Extensive research in the field of kinase inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of kinase inhibitors in their productions and processes. This has led to the steady market for them.

 

R&D spending along with increasing competition, patent expiries and new technologies are directing kinase inhibitors to new directions. The new advancements, new product launches and the changing lifestyle have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

 

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/ technology in light of the new technologies, growing competition and changing customer needs.

 

INTENDED AUDIENCE

 

This study contributes to the areas of market growth in kinase inhibitor manufacture and use. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.

 

SCOPE OF THE STUDY

 

The scope of this study encompasses kinase inhibitors in pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand and others countries.

 

METHODOLOGY

 

Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

 

INFORMATION SOURCES

 

Many companies active in the kinase inhibitor industry were surveyed to obtain data for this study. Included were manufacturers and end users of kinase inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were conducted. In addition, data were compiled from current financial, trade and government sources.

 

ABOUT THE AUTHOR

 

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are: Reagents for Chromatography; Spectroscopy - An Enduring Market; Advanced Drug Delivery Systems - Technologies and Global Markets; Orthopedic Drugs, Implants and Devices - Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry - The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging - Global Markets; Chiral Technology - Global Markets; Autacoids and Related Drugs - Technologies and Global Markets; Contraceptives - Technologies and Global Markets; Liver Disease Treatments - The Global Market; Hormone Replacement Therapies and Other Hormone Therapies - Global Markets; Cardiovascular Medicine - Diagnostics, Drugs and Devices; and Cancer Therapies - Technologies and Global Markets.

 

 

 

TABLE OF CONTENTS

 

CHAPTER 1 INTRODUCTION 1

STUDY OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 1

SCOPE OF THE STUDY 1

METHODOLOGY 2

INFORMATION SOURCES 2

ABOUT THE AUTHOR 2

RELATED BCC RESEARCH REPORTS 2

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER 2 SUMMARY 5

SUMMARY TABLE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 ($

MILLIONS) 6

SUMMARY FIGURE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016 ($

MILLIONS) 6

CHAPTER 3 OVERVIEW 8

DEFINITIONS 8

ENZYME INHIBITORS 8

WHY ENZYME INHIBITION? 8

USE OF ENZYME INHIBITORS 9

Mechanism of Enzyme Inhibition 9

Types of Enzyme Inhibitors 9

CLASSIFICATION OF ENZYME INHIBITORS 10

TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 10

KINASE INHIBITORS 11

HISTORY OF PROTEIN KINASES 12

TABLE 2 HISTORY OF PROTEIN KINASES 12

TYPES OF KINASE INHIBITORS 13

TABLE 3 TYPES OF KINASE INHIBITORS 13

Small Molecule Inhibitors 13

TABLE 4 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS 14

Antibody (Monoclonal) Inhibitors 14

CLASSIFICATION BY TYPES OF AMINO ACID PHOSPHORYLATION 14

SERINE/THREONINE KINASE INHIBITORS 14

TABLE 5 TYPES OF SERINE/THREONINE KINASE INHIBITORS 15

TYROSINE KINASE INHIBITORS 15

Receptor Tyrosine Kinase (RTK) Inhibitors 16

TABLE 6 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS 16

Non-Receptor Tyrosine Kinase (NRTK) Inhibitors 16

TABLE 7 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS 16

CLASSIFICATION BY SITE OF ACTION 17

TABLE 8 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION 17

CHAPTER 4 REGULATORY ASPECTS 20

TABLE 9 FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012 20

TABLE 10 EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012 21

TABLE 11 SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY

2012 22

TABLE 12 NEW DRUG APPLICATIONS OF KINASE INHIBITORS 23

MARKET LEADERS AND THEIR PRODUCTS FOR KINASE INHIBITORS 24

TABLE 13 LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE

INHIBITORS 24

TABLE 14 LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE

KINASE INHIBITORS 24

TABLE 15 LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE

KINASE INHIBITORS 24

TABLE 16 LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE

KINASE INHIBITORS 25

TABLE 17 LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS 25

CHAPTER 5 NEW DEVELOPMENTS 27

(RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS) 27

TABLE 18 CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS 27

TABLE 19 CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)

TKIS 28

TABLE 20 CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR)

TKIS 28

TABLE 21 CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR

(VEGFR) TKIS 28

(NON-RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS) 29

TABLE 22 CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS 29

TABLE 23 CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS 29

TABLE 24 CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS 29

MULTIKINASE INHIBITORS 30

TABLE 25 CLINICAL TRIALS IN MULTIKINASE INHIBITORS 30

SERINE/THREONINE KINASE INHIBITOR 31

TABLE 26 CLINICAL TRIALS IN B-RAF KINASE INHIBITORS 31

TABLE 27 CLINICAL TRIALS IN MAP/MEK INHIBITORS 31

TABLE 28 CLINICAL TRIALS IN PI3K INHIBITORS 31

OTHER KINASE INHIBITOR PRODUCTS UNDER DEVELOPMENT 31

CHAPTER 6 GLOBAL MARKETS 34

MARKET ANALYSIS 34

TABLE 29 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 35

FIGURE 1 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 35

TYROSINE KINASE INHIBITORS 36

TABLE 30 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016 ($

MILLIONS) 36

FIGURE 2 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS 2009-2016 ($ MILLIONS) 36

Receptor Tyrosine Kinase Inhibitors 37

EGFR 37

PDGFR 38

VEGFR 38

HER2 39

Market Overview 39

Market Revenue 40

TABLE 31 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016

($ MILLIONS) 40

FIGURE 3 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 40

Non-Receptor Tyrosine Kinase Inhibitors 40

BCR-ABL 41

Janus Kinase (JAK) Inhibitor 41

Mesenchymal Epithelial Transition Growth Factor (c-MET) 41

Spleen Tyrosine Kinase (SYK) Inhibitors 42

Market Overview 42

Market Revenue 42

TABLE 32 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH

2016 ($ MILLIONS) 43

FIGURE 4 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016

($ MILLIONS) 43

Multikinase Inhibitors 43

Market Overview 44

Market Revenue 44

TABLE 33 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016 ($

MILLIONS) 45

FIGURE 5 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($

MILLIONS) 45

SERINE/THREONINE KINASE INHIBITORS 45

mTOR Kinase Inhibitors 45

B RAF 46

RHO Kinase Inhibitors 46

Cyclin Dependant Kinase Inhibitor 46

Aurora Kinase Inhibitors 46

MAP/MEK Kinase Inhibitors 47

JNK Inhibitors 47

Protein Kinase C Inhibitors 47

PI3K Inhibitors 48

Market Overview 48

Market Revenue 48

TABLE 34 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016 ($

MILLIONS) 49

FIGURE 6 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($

MILLIONS) 49

MONOCLONAL ANTIBODY KINASE INHIBITOR 49

Humanized Monoclonal Antibody 50

Chimeric Monoclonal Antibody 50

Human Monoclonal Antibody 51

Market Overview 51

Market Revenue 52

TABLE 35 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH

2016 ($ MILLIONS) 52

FIGURE 7 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, 2009-2016

($ MILLIONS) 52

MARKET SHARE 53

RECEPTOR TYROSINE KINASE INHIBITORS 53

TABLE 36 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53

FIGURE 8 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53

NON-RECEPTOR TYROSINE KINASE INHIBITORS 54

MULTI-TARGET KINASE INHIBITORS 54

TABLE 37 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54

FIGURE 9 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54

SERINE/THREONINE KINASE INHIBITORS 55

TABLE 38 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55

FIGURE 10 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55

MONOCLONAL ANTIBODY KINASE INHIBITORS 56

TABLE 39 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010

(%) 56

FIGURE 11 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION,

2010 (%) 56

MARKET BY APPLICATIONS 57

MARKET REVENUE 58

TABLE 40 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016 ($

MILLIONS) 59

FIGURE 12 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016 ($

MILLIONS) 59

ANTINEOPLASTIC AGENTS 59

TABLE 41 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

THROUGH 2016 ($ MILLIONS) 63

FIGURE 13 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

2009-2016 ($ MILLIONS) 63

IMMUNOSUPPRESSANTS 63

TABLE 42 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

THROUGH 2016 ($ MILLIONS) 64

FIGURE 14 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

2009-2016 ($ MILLIONS) 64

AGE-RELATED MACULAR DEGENERATION 65

TABLE 43 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, THROUGH 2016 ($ MILLIONS) 66

FIGURE 15 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, 2009-2016 ($ MILLIONS) 66

MARKET SHARE 67

TABLE 44 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 67

FIGURE 16 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 67

CHAPTER 7 MARKETS IN THE UNITED STATES 69

MARKET ANALYSIS 69

TABLE 45 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69

FIGURE 17 U.S. MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69

TYROSINE KINASE INHIBITORS 70

TABLE 46 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 71

FIGURE 18 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 71

Receptor Tyrosine Kinase Inhibitors 71

EGFR 72

PDGFR 72

VEGFR 72

HER2 73

Market Overview 73

Market Revenue 74

TABLE 47 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016 ($

MILLIONS) 74

FIGURE 19 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 74

Non-Receptor Tyrosine Kinase Inhibitors 75

BCR-ABL 75

Janus Kinase (JAK) Inhibitor 76

Mesenchymal Epithelial Transition Growth Factor (c-MET) 76

Spleen Tyrosine Kinase (SYK) Inhibitors 76

Market Overview 77

Market Revenue 77

TABLE 48 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH

2016 ($ MILLIONS) 77

FIGURE 20 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 77

Multikinase Inhibitors 78

Market Overview 78

Market Revenue 79

TABLE 49 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, THROUGH 2016 ($

MILLIONS) 80

FIGURE 21 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($ MILLIONS) 80

SERINE/THREONINE KINASE INHIBITORS 80

M TOR Kinase Inhibitors 80

B RAF 81

RHO Kinase Inhibitors 81

Cyclin Dependant Kinase Inhibitor 81

Aurora Kinase Inhibitors 81

MAP/MEK Kinase Inhibitors 82

JNK Inhibitors 82

Protein Kinase C Inhibitors 82

PI3K Inhibitors 83

Market Overview 83

Market Revenue 84

TABLE 50 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, THROUGH 2016 ($

MILLIONS) 84

FIGURE 22 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 85

MONOCLONAL ANTIBODY KINASE INHIBITOR 85

Humanized Monoclonal Antibody 86

Chimeric Monoclonal Antibody 87

Human Monoclonal Antibody 87

Market Overview 87

Market Revenue 88

TABLE 51 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH 2016

($ MILLIONS) 88

FIGURE 23 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR 2009-2016 ($

MILLIONS) 88

MARKET SHARE OF INDUSTRY LEADERS IN U.S 89

RECEPTOR TYROSINE KINASE INHIBITORS 89

TABLE 52 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 89

FIGURE 24 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 89

NON-RECEPTOR TYROSINE KINASE INHIBITORS 90

MULTI-TARGET KINASE INHIBITORS 90

TABLE 53 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,

2010 (%) 90

FIGURE 25 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,

2010 (%) 90

SERINE/ THREONINE KINASE INHIBITORS 91

TABLE 54 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 91

FIGURE 26 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 91

ANTIBODY KINASE INHIBITORS 92

TABLE 55 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010

(%) 92

FIGURE 27 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010

(%) 92

MARKET APPLICATIONS 93

MARKET REVENUE 94

TABLE 56 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, THROUGH 2016 ($

MILLIONS) 94

FIGURE 28 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($

MILLIONS) 94

ANTINEOPLASTIC AGENTS 95

TABLE 57 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

THROUGH 2016 ($ MILLIONS) 98

FIGURE 29 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

2009-2016 ($ MILLIONS) 98

IMMUNOSUPPRESSANTS 99

TABLE 58 U.S. MARKET FOR KINASE INHIBITORS USED AS

IMMUNOSUPPRESSANTS,THROUGH 2016 ($ MILLIONS) 100

FIGURE 30 U.S. MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

2009-2016 ($ MILLIONS) 100

AGE-RELATED MACULAR DEGENERATION 101

TABLE 59 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, THROUGH 2016 ($ MILLIONS) 102

FIGURE 31 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, 2009-2016 ($ MILLIONS) 102

MARKET SHARE 103

TABLE 60 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103

FIGURE 32 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103

CHAPTER 8 PATENT ANALYSIS 105

PATENTS BY YEAR 105

TABLE 61 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 105

FIGURE 33 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 105

FIGURE 34 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 (%) 106

PATENTS BY CATEGORY 106

TABLE 62 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY

2012 107

FIGURE 35 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY

2012 107

PATENTS BY TYPE 107

TABLE 63 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF

FEBRUARY 2012 107

FIGURE 36 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF

FEBRUARY 2012 108

TABLE 64 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END

OF FEBRUARY 2012 108

FIGURE 37 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END

OF FEBRUARY 2012 108

PATENTS BY COMPANY 109

TABLE 65 NUMBER OF U.S. PATENTS BY COMPANY FOR INDUSTRIAL ENZYMES, 2008 TO

END OF FEBRUARY 2012 109

PATENTS BY COUNTRY 110

TABLE 66 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END

OF FEBRUARY 2012 110

FIGURE 38 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO

END OF FEBRUARY 2012 110

TABLE 67 PATENT SHARE BY COUNTRY FOR KINASE INHIBITORS, 2010–2012 (%) 111

FIGURE 39 PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010–2012 (%) 111

PATENTS BY ASSIGNEE 112

TABLE 68 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF

FEBRUARY 2012 112

FIGURE 40 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF

FEBRUARY 2012 112

CHAPTER 9 CURRENT STATUS 115

CANCER AND KINASE INHIBITORS 115

MULTIPLE SINGLE KINASE INHIBITORS VERSUS SINGLE MULTIKINASE INHIBITORS 115

EFFICACY 116

RESISTANCE 116

PHARMACOKINETICS 117

Selectivity 117

TUMOR MICROENVIRONMENT 117

TOXICITY 118

FUTURE DIRECTIONS 118

CHAPTER 10 COMPANY PROFILES 120

ABBOTT LABORATORIES 120

AMGEN INC. 120

ARQULE, INC. 121

ARRAY BIOPHARMA 121

ASTRAZENECA 121

AVEO PHARMACEUTICALS, INC. 122

BAYER AG 122

BRISTOL-MYERS SQUIBB 123

BOEHRINGER INGELHEIM 123

CYTRX CORPORATION 123

EISAI INC 124

ETON BIOSCIENCE, INC. 124

EXELIXIS, INC. 124

GLAXOSMITHKLINE 125

MERCK SERONO SA 125

NOVARTIS INTERNATIONAL AG 126

OSI PHARMACEUTICALS LLC 126

PFIZER 127

ROCHE GROUP 127

S*BIO PTE LTD 128

SANOFI-AVENTIS 128

TAKEDA PHARMACEUTICALS 129

CHAPTER 11 APPENDIX: ABBREVIATIONS 131

 

LIST OF TABLES

SUMMARY TABLE GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 ($

MILLIONS) 6

TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 10

TABLE 2 HISTORY OF PROTEIN KINASES 12

TABLE 3 TYPES OF KINASE INHIBITORS 13

TABLE 4 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS 14

TABLE 5 TYPES OF SERINE/THREONINE KINASE INHIBITORS 15

TABLE 6 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS 16

TABLE 7 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS 16

TABLE 8 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION 17

TABLE 9 FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012 20

TABLE 10 EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012 21

TABLE 11 SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY

2012 22

TABLE 12 NEW DRUG APPLICATIONS OF KINASE INHIBITORS 23

TABLE 13 LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE

INHIBITORS 24

TABLE 14 LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE

KINASE INHIBITORS 24

TABLE 15 LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE

KINASE INHIBITORS 24

TABLE 16 LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE KINASE

INHIBITORS 25

TABLE 17 LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS 25

TABLE 18 CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TKIS 27

TABLE 19 CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)

TKIS 28

TABLE 20 CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR)

TKIS 28

TABLE 21 CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR

(VEGFR) TKIS 28

TABLE 22 CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS 29

TABLE 23 CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS 29

TABLE 24 CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS 29

TABLE 25 CLINICAL TRIALS IN MULTIKINASE INHIBITORS 30

TABLE 26 CLINICAL TRIALS IN B-RAF KINASE INHIBITORS 31

TABLE 27 CLINICAL TRIALS IN MAP/MEK INHIBITORS 31

TABLE 28 CLINICAL TRIALS IN PI3K INHIBITORS 31

TABLE 29 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 35

TABLE 30 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016 ($

MILLIONS) 36

TABLE 31 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016 ($

MILLIONS) 40

TABLE 32 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH

2016 ($ MILLIONS) 43

TABLE 33 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016 ($

MILLIONS) 45

TABLE 34 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016 ($

MILLIONS) 49

TABLE 35 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH

2016 ($ MILLIONS) 52

TABLE 36 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53

TABLE 37 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54

TABLE 38 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55

TABLE 39 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010

(%) 56

TABLE 40 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016 ($

MILLIONS) 59

TABLE 41 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

THROUGH 2016 ($ MILLIONS) 63

TABLE 42 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

THROUGH 2016 ($ MILLIONS) 64

TABLE 43 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, THROUGH 2016 ($ MILLIONS) 66

TABLE 44 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 67

TABLE 45 U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 69

TABLE 46 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, THROUGH 2016 ($ MILLIONS) 71

TABLE 47 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016 ($

MILLIONS) 74

TABLE 48 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, THROUGH 2016

($ MILLIONS) 77

TABLE 49 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, THROUGH 2016 ($

MILLIONS) 80

TABLE 50 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, THROUGH 2016 ($

MILLIONS) 84

TABLE 51 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH 2016

($ MILLIONS) 88

TABLE 52 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 89

TABLE 53 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,

2010 (%) 90

TABLE 54 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 91

TABLE 55 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010 (%) 92

TABLE 56 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, THROUGH 2016 ($

MILLIONS) 94

TABLE 57 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

THROUGH 2016 ($ MILLIONS) 98

TABLE 58 U.S. MARKET FOR KINASE INHIBITORS USED AS

IMMUNOSUPPRESSANTS,THROUGH 2016 ($ MILLIONS) 100

TABLE 59 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, THROUGH 2016 ($ MILLIONS) 102

TABLE 60 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103

TABLE 61 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 105

TABLE 62 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY

2012 107

TABLE 63 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF FEBRUARY

2012 107

TABLE 64 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END OF

FEBRUARY 2012 108

TABLE 65 NUMBER OF U.S. PATENTS BY COMPANY FOR INDUSTRIAL ENZYMES, 2008 TO

END OF FEBRUARY 2012 109

TABLE 66 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END

OF FEBRUARY 2012 110

TABLE 67 PATENT SHARE BY COUNTRY FOR KINASE INHIBITORS, 2010–2012 (%) 111

TABLE 68 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF

FEBRUARY 2012 112

 

LIST OF FIGURES

INHIBITORS MARKET, 2009-2016 ($

MILLIONS) 6

FIGURE 1 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 35

FIGURE 2 GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS 2009-2016 ($ MILLIONS) 36

FIGURE 3 GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 40

FIGURE 4 GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016

($ MILLIONS) 43

FIGURE 5 GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($

MILLIONS) 45

FIGURE 6 GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016 ($

MILLIONS) 49

FIGURE 7 GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 52

FIGURE 8 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53

FIGURE 9 MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 54

FIGURE 10 SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 55

FIGURE 11 MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010

(%) 56

FIGURE 12 GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016 ($

MILLIONS) 59

FIGURE 13 GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

2009-2016 ($ MILLIONS) 63

FIGURE 14 GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

2009-2016 ($ MILLIONS) 64

FIGURE 15 GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, 2009-2016 ($ MILLIONS) 66

FIGURE 16 GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010 (%) 67

FIGURE 17 U.S. MARKET FOR KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 69

FIGURE 18 U.S. MARKET FOR TYROSINE KINASE INHIBITORS, 2009-2016 ($ MILLIONS) 71

FIGURE 19 U.S. MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 74

FIGURE 20 U.S. MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 77

FIGURE 21 U.S. MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016 ($ MILLIONS) 80

FIGURE 22 U.S. MARKET FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016 ($

MILLIONS) 85

FIGURE 23 U.S. MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR 2009-2016 ($

MILLIONS) 88

FIGURE 24 U.S. MARKET SHARES OF RECEPTOR TYROSINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 89

FIGURE 25 U.S. MARKET SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS,

2010 (%) 90

FIGURE 26 U.S. MARKET SHARES OF SERINE/ THREONINE KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 91

FIGURE 27 U.S. MARKET SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS, 2010

(%) 92

FIGURE 28 U.S. MARKET FOR KINASE INHIBITORS BY APPLICATION, 2009-2016 ($ MILLIONS) 94

FIGURE 29 U.S. MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS,

2009-2016 ($ MILLIONS) 98

FIGURE 30 U.S. MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS,

2009-2016 ($ MILLIONS) 100

FIGURE 31 U.S. MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR

DEGENERATION, 2009-2016 ($ MILLIONS) 102

FIGURE 32 MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS IN U.S., 2010 (%) 103

FIGURE 33 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 105

FIGURE 34 NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012 (%) 106

FIGURE 35 PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY

2012 107

FIGURE 36 PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF

FEBRUARY 2012 108

FIGURE 37 PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END

OF FEBRUARY 2012 108

FIGURE 38 NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END

OF FEBRUARY 2012 110

FIGURE 39 PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010–2012 (%) 111

FIGURE 40 PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF

FEBRUARY 2012 112

 

 

 

To order this report:

Therapy Industry: Kinase Inhibitors: Global Markets -- Focus on the U.S.

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced the appointment of ... surgeon, industry consultant, and private healthcare investor, to its ... healthcare leader with clinical and strategic experience at the ... Chairman and CEO. "As one of the world,s leading ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today that it ... for AC0010 at the World Conference on Lung Cancer 2016, taking place in Vienna, ... phase I/II clinical trials for AC0010 in patients with advanced non-small cell lung cancer ...
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom Healthcare ( ... hospitals, will present its chain-of-custody solution for tracking and securing medications at booth ... Dec. 4-8, 2016. , Aerocom has a proven solution for tracking medications via ...
(Date:12/2/2016)... ... 2016 , ... The Conference Forum has announced that the 3rd annual ... on February 1-3, 2017 at the Roosevelt Hotel in New York City. Led by ... unique 360-degree approach, which addresses the most up-to-date information regarding business aspects, clinical advancements ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/29/2016)... 29, 2016 Nearly one billion matches per second ... ... DERMALOG is Germany's ... efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification ...
(Date:11/22/2016)... -- According to the new market research report "Biometric System ... Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and ... expected to grow from USD 10.74 Billion in 2015 to reach USD ... 2022. Continue Reading ... ...
Breaking Biology News(10 mins):